EVG.L Regulatory News (EVG)

Evgen Pharma plc

 ("Evgen Pharma" or "the Company")

Update re SFX-01 Data at ECTRIMS 2016

Evgen Pharma plc (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, is pleased to announce, further to its announcement on 8 September 2016, that the abstract and poster relating to the results of its preclinical study of SFX-01 in various models of the relapsing remitting form of multiple sclerosis are now available on the Company's website.

The preclinical study focused on the comparison of SFX-01 with dimethyl fumarate, the active principle in BG-12, which is marketed as Tecfidera®.

In addition to this completed preclinical study, Evgen Pharma has ongoing clinical studies of SFX-01. A Phase II study in subarachnoid haemorrhage is currently underway and the first patient is expected to be dosed shortly in a Phase II study in breast cancer.

The preclinical study data in multiple sclerosis are being presented this week in London at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).

The poster, entitled Efficacy of SFX-01, a sulforaphane-based drug in experimental autoimmune encephalomyelitis, is available at this link: http://evgen.com/wp-content/uploads/2016/09/ECTRIMS-2016-POSTER-.pdf

The abstract of the poster is at this link: http://evgen.com/wp-content/uploads/2016/09/ECTRIMS-2016-ABSTRACT.pdf

As stated in the announcement on 8 September 2016, the Company is conducting a commercial appraisal of the potential of SFX-01 in multiple sclerosis and will give a further update to shareholders later this year.

Enquiries:

Notes for editors:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. It is also carrying out preclinical work in multiple sclerosis and has a clinical interest in prostate cancer. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

Evgen Pharma commenced operations in January 2008 and is based in Liverpool, UK, at the Liverpool Science Park.  It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.  For further information please visit www.evgen.com